Table 1.
Studies evaluating risk of hemorrhage and thromboembolism after ICH
| First Author | Design | No. | Patients with OAC resumption | Patients without OAC resumption | HR (95% CI) of OAC resumption | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time of OAC restarting (days) | Incidence of recurrent ICH* | Incidence of TE* | Incidence all-cause mortality* | Incidence of recurrent ICH* | Incidence of TE* | Incidence all-cause mortality* | ICH | TE | All-cause mortality | |||
| Ottosen [1•] | Population-based cohort | 6369 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.90 (0.44–1.82) | 0.58 (0.35–0.97) | 0.59 (0.43–0.82) |
| Witt [14] | Retrospective cohort | 160 | 14 | 7.6 | 3.7 | 18.5 | 3.7 | 12.3 | 31.1 | 0.47 (0.10–2.30) | 0.28 (0.06–1.27) | 0.76 (0.30–1.89) |
| Nielsen [15••] | Nationwide cohort | 1752 | 34 | 8.0 | 5.3 | 9.7 | 8.6 | 10.4 | 19.1 | 0.91 (0.56–1.49) | 0.59 (0.33–1.03) | 0.55 (0.37–0.82) |
| Kuramatsu [16] | Nationwide cohort | 719 | 31 | 3.9 | 5.2 | 8.2 | 3.9 | 15.0 | 37.5 | N/A | N/A | 0.26 (0.13–0.53) |
| Nielsen [17••] | Nationwide cohort | 2415 | 31 | 5.8 | 3.3 | 19.6 | 5.3 | 8. 9 | 35.5 | 1.31 (0.68–2.50) | 0.43 (0.21–0.86) | 0.51 (0.37–0.71) |
| Santosh [18] | Meta-analysis | 5306 | N/A | N/A | N/A | N/A | 7.8 | N/A | N/A | 1.01 (0.58–1.77) | 0.34 (0.25–0.45) | N/A |
| Poli [19] | Nationwide cohort | 244 | N/A | N/A | 2.0 | 3.0 | N/A | 6.0 | 8.0 | N/A | 0.19 (0.06–0.60) | 0.17 (0.06–0.45) |
| Park [20] | Retrospective | 528 | 117 | 1.4 | 2.4 | 1.4 | 0 | 8.3 | 4.8 | N/A | 0.19 (0.08–0.47) | N/A |
HR hazard ratio, CI confidence interval, ICH intracerebral hemorrhage, OAC oral anticoagulants, TE thromboembolism
*Per 100 person-years